Democratic senators introduce registry legislation

Share this article:
A group of Democratic senators has introduced a bill that would require drug makers and medical device manufacturers to register clinical trials of their products in a public database at their onset and report subsequent test results. The legislation would require registration before clinical trials involving patients could be conducted.
Several drug companies have already indicated they will start posting trial results on company Web sites, a perceived reaction to mounting pressure from medical editors who say they will not publish papers on clinical trial results unless they have been publicly accessible since trial outset. The American Medical Association also has passed a resolution calling for a similar national database.
It is unlikely that action on the bill would be taken until after the presidential election. Sponsors of the bill included Senators Edward Kennedy of Massachusetts, Christopher Dodd of Connecticut, Tim Johnson of South Dakota and Ron Wyden of Oregon.
Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...